JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eddy, N. B.
Right arrow Articles by Lee, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eddy, N. B.
Right arrow Articles by Lee, L. E., Jr.
Journal of Pharmacology And Experimental Therapeutics, Vol. 125, Issue 2, 116-121, 1959
Copyright © 1959 by American Society for Pharmacology and Experimental Therapeutics

THE ANALGESIC EQUIVALENCE TO MORPHINE AND RELATIVE SIDE ACTION LIABILITY OF OXYMORPHONE (4-HYDROXYDIHYDROMORPHINONE)

Nathan B. Eddy 1 and Lyndon E. Lee Jr. 1

1 Section on Analgesics, Laboratory of Chemistry, National Institute of Arthritis and Metabolic Diseases, National Institutes of Health, Department of Health, Education and Welfare, Bethesda, Maryland

Oxymorphone (14-hydroxydihydromorphinone) has been compared in the same patients with morphine and a placebo for its effectiveness against chronic pain due to neoplastic disease. Under these conditions 1.02 mg of oxymorphone hydrochloride is equivalent to 10 mg of morphine sulfate. The limits of error (P = 0.99) were 61-164%. These doses of the two drugs are not materially different in peak or duration of analgesic effect. If the dose of oxymorphone was increased to 2.0 mg, the peak effect was increased and analgesia was somewhat better sustained, but the over-all duration of effect was not greater than with 12.0 mg of morphine. The side effects of equipotent analgesic doses were slightly less for oxymorphone; at least there appeared to be less nausea and vomiting. An increase in the dose of oxymorphone, however, increases the side effects and may be accompanied by severe respiratory depression in debilitated individuals, possibly to a greater extent than with morphine.

Submitted on September 9, 1958




This article has been cited by other articles:


Home page
 J Clin PharmacolHome page
M. Adams, H. J. Pieniaszek Jr, A. R. Gammaitoni, and H. Ahdieh
Oxymorphone Extended Release Does Not Affect CYP2C9 or CYP3A4 Metabolic Pathways
J. Clin. Pharmacol., March 1, 2005; 45(3): 337 - 345.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
J. Gimbel and H. Ahdieh
The Efficacy and Safety of Oral Immediate-Release Oxymorphone for Postsurgical Pain
Anesth. Analg., November 1, 2004; 99(5): 1472 - 1477.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
H. Ahdieh, T. Ma, N. Babul, and D. Lee
Efficacy of Oxymorphone Extended Release in Postsurgical Pain: A Randomized Clinical Trial in Knee Arthroplasty
J. Clin. Pharmacol., July 1, 2004; 44(7): 767 - 776.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
W. T. Beaver, S. L. Wallenstein, R. W. Houde, and A. Rogers
Comparisons of the Analgesic Effects of Oral and Intramuscular Oxymorphone and of Intramuscular Oxymorphone and Morphine in Patients with Cancer
J. Clin. Pharmacol., April 1, 1977; 17(4): 186 - 198.
[PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1959 by the American Society for Pharmacology and Experimental Therapeutics.